EA201071138A1 - Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона - Google Patents

Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона

Info

Publication number
EA201071138A1
EA201071138A1 EA201071138A EA201071138A EA201071138A1 EA 201071138 A1 EA201071138 A1 EA 201071138A1 EA 201071138 A EA201071138 A EA 201071138A EA 201071138 A EA201071138 A EA 201071138A EA 201071138 A1 EA201071138 A1 EA 201071138A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dronedarone
patients
increased
treatment
level
Prior art date
Application number
EA201071138A
Other languages
English (en)
Inventor
Софи Клодель
Кристоф Годэн
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39680951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA201071138A1 publication Critical patent/EA201071138A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)

Abstract

Применение дронедарона или одной из его фармацевтически приемлемых солей для получения лекарственного средства для лечения пациентов с аритмией, причем указанные пациенты имеют увеличенный уровень креатинина вследствие введения дронедарона, причем указанный уровень креатинина повышается в результате инициирования лечения дронедароном, причем указанное увеличение уровня креатинина достигает плато и используется в качестве нового контрольного уровня, причем указанное увеличение уровня креатинина является обратимым после прекращения введения дронедарона.
EA201071138A 2008-04-28 2009-04-28 Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона EA201071138A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4873208P 2008-04-28 2008-04-28
EP08290407A EP2116239A1 (en) 2008-04-29 2008-04-29 Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
PCT/IB2009/005930 WO2009133470A2 (en) 2008-04-28 2009-04-28 Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration

Publications (1)

Publication Number Publication Date
EA201071138A1 true EA201071138A1 (ru) 2011-06-30

Family

ID=39680951

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071138A EA201071138A1 (ru) 2008-04-28 2009-04-28 Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона

Country Status (27)

Country Link
US (1) US20100016423A1 (ru)
EP (2) EP2116239A1 (ru)
JP (1) JP2011518872A (ru)
KR (1) KR20100135853A (ru)
CN (1) CN102076337A (ru)
AR (1) AR072954A1 (ru)
AU (1) AU2009241286A1 (ru)
BR (1) BRPI0912706A2 (ru)
CA (1) CA2722815A1 (ru)
CL (1) CL2009001018A1 (ru)
CO (1) CO6311076A2 (ru)
DO (1) DOP2010000327A (ru)
EA (1) EA201071138A1 (ru)
EC (1) ECSP10010567A (ru)
IL (1) IL208900A0 (ru)
MA (1) MA32299B1 (ru)
MX (1) MX2010011873A (ru)
NI (1) NI201000181A (ru)
NZ (1) NZ588886A (ru)
PA (1) PA8824601A1 (ru)
PE (1) PE20091885A1 (ru)
SG (1) SG188180A1 (ru)
TW (1) TW200948355A (ru)
UA (1) UA100883C2 (ru)
UY (1) UY31790A (ru)
WO (1) WO2009133470A2 (ru)
ZA (1) ZA201007727B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102065855A (zh) 2008-04-17 2011-05-18 赛诺菲-安万特 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone
RU2456019C1 (ru) * 2011-03-29 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития жизнеопасных желудочковых аритмий у пациентов без структурных изменений сердца

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
HUP0104249A3 (en) * 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
DE60117857D1 (de) * 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
GB0611210D0 (en) * 2006-06-07 2006-07-19 Cambrex Karlskoga Ab Process
DE102006035912A1 (de) * 2006-07-31 2008-02-07 Südzucker AG Mannheim/Ochsenfurt Verwendung von Isomaltulose in regenerativ wirkenden Nahrungsmitteln
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
CN102065855A (zh) * 2008-04-17 2011-05-18 赛诺菲-安万特 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2133075A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EP2153830A1 (en) * 2008-08-07 2010-02-17 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack

Also Published As

Publication number Publication date
CA2722815A1 (en) 2009-11-05
US20100016423A1 (en) 2010-01-21
UA100883C2 (ru) 2013-02-11
CN102076337A (zh) 2011-05-25
EP2291183A2 (en) 2011-03-09
TW200948355A (en) 2009-12-01
KR20100135853A (ko) 2010-12-27
MX2010011873A (es) 2011-04-05
ECSP10010567A (es) 2010-11-30
IL208900A0 (en) 2011-01-31
JP2011518872A (ja) 2011-06-30
DOP2010000327A (es) 2011-01-31
ZA201007727B (en) 2013-01-30
NI201000181A (es) 2012-03-15
WO2009133470A2 (en) 2009-11-05
BRPI0912706A2 (pt) 2017-06-13
AU2009241286A1 (en) 2009-11-05
WO2009133470A3 (en) 2009-12-23
NZ588886A (en) 2013-01-25
MA32299B1 (fr) 2011-05-02
EP2116239A1 (en) 2009-11-11
PE20091885A1 (es) 2009-12-31
PA8824601A1 (es) 2009-12-16
UY31790A (es) 2009-12-14
AR072954A1 (es) 2010-10-06
CL2009001018A1 (es) 2011-01-07
CO6311076A2 (es) 2011-08-22
SG188180A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
JP2013522184A5 (ru)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
PE20110943A1 (es) Formulacion oral solida de alisquireno
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
DOP2012000012A (es) Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
AR083337A1 (es) Tratamientos de infeccion por el virus de hepatitis c
JP2016505628A5 (ru)
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
AR080499A1 (es) El uso de dronedarona o una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para la administracion poco despues de la interrupcion de amiodarona
TH112377B (th) การใช้โดรนดาโรนสำหรับเตรียมเภสัชภัณฑ์สำหรับการรักษาผู้ป่วยที่มีภาวะหัวใจเสียจังหวะและมีการเพิ่มระดับครีเอทินินเนื่องจากการให้โดรนดาโรน
CR11745A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatina debido a la administracion de dronedarona